RemedyLogic
AI-powered MRI interpretation for spine care — an FDA-cleared diagnostic platform that structures diagnosis and treatment pathways in musculoskeletal medicine.
AI-powered MRI interpretation for spine care — an FDA-cleared diagnostic platform that structures diagnosis and treatment pathways in musculoskeletal medicine.
Musculoskeletal treatment decisions begin with imaging — and MRI interpretation has remained unstructured, variable, and expensive. RemedyLogic builds the interpretation layer: AI that reads spine MRI studies and produces structured, consistent diagnostic output that downstream diagnosis and treatment decisions can rely on.
The company’s thesis is that whoever structures the interpretation shapes the pathway — connecting imaging to diagnosis to appropriate treatment in one consistent logic, in a specialty where care today varies widely by provider.
The company in brief — tap any section to open it.
RemedyLogic has built a proprietary vision-language model that interprets spine MRI studies and structures the findings into consistent diagnostic output — a platform the company reports is FDA-cleared. Structured interpretation is the foundation for consistent diagnosis and treatment pathways in musculoskeletal care.
The company reports distribution partnerships with Siemens and Microsoft/Nuance, giving its platform reach across a broad share of U.S. radiology infrastructure without building hospital-by-hospital integrations.
Per the company, anchor deployments include Orlando Health, Mount Sinai, Cedars-Sinai, and SimonMed — health systems integrating structured MRI interpretation into clinical workflows.
RemedyLogic is led by founder and CEO Andrej Rusakov.
RemedyLogic fits AMP’s frontier-technology thesis: AI infrastructure for a large, high-friction clinical workflow, distributed through the systems radiology already runs on rather than sold seat by seat.
Company information on this page is based on statements by RemedyLogic and public sources and has not been independently verified by AMP.